KRMD Repro Med Systems Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KRMD

Price (delayed)

$2.28

Market cap

$104.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.28

Enterprise value

$97.69M

Repro Med Systems, Inc. dba KORU Medical System develops, manufactures, and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM ...

Highlights
The gross profit is up by 11% year-on-year and by 6% since the previous quarter
The gross margin has grown by 10% YoY and by 2.7% from the previous quarter
The net income has dropped by 55% year-on-year but it has increased by 3.5% since the previous quarter
KRMD's EPS is down by 47% year-on-year but it is up by 7% since the previous quarter
The company's equity fell by 36% YoY and by 6% QoQ
The quick ratio has contracted by 17% YoY and by 9% from the previous quarter
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.repro-med.com
Peers: NVRO OFIX NURO

Key stats

What are the main financial stats of KRMD
Market
Shares outstanding
45.76M
Market cap
$104.34M
Enterprise value
$97.69M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.45
Price to sales (P/S)
3.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.33
Earnings
Revenue
$29.32M
EBIT
-$8.72M
EBITDA
-$7.83M
Free cash flow
-$1.22M
Per share
EPS
-$0.28
Free cash flow per share
-$0.03
Book value per share
$0.42
Revenue per share
$0.64
TBVPS
$0.59
Balance sheet
Total assets
$27.5M
Total liabilities
$8.38M
Debt
$4.17M
Equity
$19.12M
Working capital
$14.63M
Liquidity
Debt to equity
0.22
Current ratio
4.01
Quick ratio
3.19
Net debt/EBITDA
0.85
Margins
EBITDA margin
-26.7%
Gross margin
60.2%
Net margin
-45.2%
Operating margin
-31.3%
Efficiency
Return on assets
-41.7%
Return on equity
-55.9%
Return on invested capital
-43.9%
Return on capital employed
-38.5%
Return on sales
-29.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KRMD stock price

How has the Repro Med Systems stock price performed over time
Intraday
-4.2%
1 week
4.11%
1 month
-6.17%
1 year
-44.25%
YTD
-7.13%
QTD
-3.39%

Financial performance

How have Repro Med Systems's revenue and profit performed over time
Revenue
$29.32M
Gross profit
$17.66M
Operating income
-$9.17M
Net income
-$13.27M
Gross margin
60.2%
Net margin
-45.2%
The net income has dropped by 55% year-on-year but it has increased by 3.5% since the previous quarter
KRMD's net margin has dropped by 54% year-on-year but it is up by 6% since the previous quarter
The company's operating margin rose by 15% YoY and by 13% QoQ
KRMD's operating income is up by 14% YoY and by 11% from the previous quarter

Growth

What is Repro Med Systems's growth rate over time

Valuation

What is Repro Med Systems stock price valuation
P/E
N/A
P/B
5.45
P/S
3.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.33
KRMD's EPS is down by 47% year-on-year but it is up by 7% since the previous quarter
The company's equity fell by 36% YoY and by 6% QoQ
KRMD's price to book (P/B) is 28% lower than its 5-year quarterly average of 7.9 but 7% higher than its last 4 quarters average of 5.3
The P/S is 48% below the 5-year quarterly average of 7.2 and 14% below the last 4 quarters average of 4.3
The revenue has grown by 2.8% from the previous quarter

Efficiency

How efficient is Repro Med Systems business performance
Repro Med Systems's ROE has plunged by 107% YoY and by 8% from the previous quarter
Repro Med Systems's return on assets has shrunk by 102% YoY and by 4.8% QoQ
KRMD's return on sales is up by 18% year-on-year and by 13% since the previous quarter
KRMD's return on invested capital is up by 2% year-on-year

Dividends

What is KRMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRMD.

Financial health

How did Repro Med Systems financials performed over time
The current ratio has contracted by 28% YoY and by 12% from the previous quarter
The total assets has contracted by 28% YoY and by 3.4% from the previous quarter
KRMD's debt is 78% smaller than its equity
The debt to equity rose by 47% YoY
The company's equity fell by 36% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.